{"id":"https://openalex.org/W2912515633","doi":"https://doi.org/10.3389/fonc.2019.00052","title":"Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors","display_name":"Tumor-Specific Delivery of Immune Checkpoint Inhibitors by Engineered AAV Vectors","publication_year":2019,"publication_date":"2019-02-14","ids":{"openalex":"https://openalex.org/W2912515633","doi":"https://doi.org/10.3389/fonc.2019.00052","mag":"2912515633","pmid":"https://pubmed.ncbi.nlm.nih.gov/30838171","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/6382738"},"language":"en","primary_location":{"id":"doi:10.3389/fonc.2019.00052","doi":"https://doi.org/10.3389/fonc.2019.00052","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2019.00052","pdf_url":"https://www.frontiersin.org/articles/10.3389/fonc.2019.00052/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.frontiersin.org/articles/10.3389/fonc.2019.00052/pdf","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5032197003","display_name":"Johanna Reul","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4391767962","display_name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung","ror":"https://ror.org/02pqn3g31","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4391767962","https://openalex.org/I4405256427"]},{"id":"https://openalex.org/I884002606","display_name":"Paul Ehrlich Institut","ror":"https://ror.org/00yssnc44","country_code":"DE","type":"facility","lineage":["https://openalex.org/I884002606"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Johanna Reul","raw_affiliation_strings":["German Cancer Consortium (DKTK), Heidelberg, Germany","Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"German Cancer Consortium (DKTK), Heidelberg, Germany","institution_ids":["https://openalex.org/I4391767962"]},{"raw_affiliation_string":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany","institution_ids":["https://openalex.org/I884002606"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5083556223","display_name":"Janina Frisch","orcid":"https://orcid.org/0009-0003-9344-1728","observed_orcids":["https://orcid.org/0009-0003-9344-1728"]},"institutions":[{"id":"https://openalex.org/I884002606","display_name":"Paul Ehrlich Institut","ror":"https://ror.org/00yssnc44","country_code":"DE","type":"facility","lineage":["https://openalex.org/I884002606"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Janina Frisch","raw_affiliation_strings":["Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany","institution_ids":["https://openalex.org/I884002606"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5050832985","display_name":"Christine E. Engeland","orcid":"https://orcid.org/0000-0001-6032-8786","observed_orcids":["https://orcid.org/0000-0001-6032-8786"]},"institutions":[{"id":"https://openalex.org/I4210111460","display_name":"National Center for Tumor Diseases","ror":"https://ror.org/01txwsw02","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I1305996414","https://openalex.org/I17937529","https://openalex.org/I223822909","https://openalex.org/I2802164966","https://openalex.org/I4210111460"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Christine E. Engeland","raw_affiliation_strings":["National Center for Tumor Diseases, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Center for Tumor Diseases, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210111460"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5016094931","display_name":"Frederic B. Thalheimer","orcid":"https://orcid.org/0000-0003-0423-099X","observed_orcids":["https://orcid.org/0000-0003-0423-099X"]},"institutions":[{"id":"https://openalex.org/I884002606","display_name":"Paul Ehrlich Institut","ror":"https://ror.org/00yssnc44","country_code":"DE","type":"facility","lineage":["https://openalex.org/I884002606"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Frederic B. Thalheimer","raw_affiliation_strings":["Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany","institution_ids":["https://openalex.org/I884002606"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076760558","display_name":"Jessica Hartmann","orcid":"https://orcid.org/0000-0001-9372-8954","observed_orcids":["https://orcid.org/0000-0001-9372-8954"]},"institutions":[{"id":"https://openalex.org/I884002606","display_name":"Paul Ehrlich Institut","ror":"https://ror.org/00yssnc44","country_code":"DE","type":"facility","lineage":["https://openalex.org/I884002606"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Jessica Hartmann","raw_affiliation_strings":["Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany","institution_ids":["https://openalex.org/I884002606"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114239057","display_name":"Guy Ungerechts","orcid":"https://orcid.org/0000-0002-3961-2368","observed_orcids":["https://orcid.org/0000-0002-3961-2368","https://orcid.org/0000-0002-2389-3644"]},"institutions":[{"id":"https://openalex.org/I4210111460","display_name":"National Center for Tumor Diseases","ror":"https://ror.org/01txwsw02","country_code":"DE","type":"healthcare","lineage":["https://openalex.org/I1305996414","https://openalex.org/I17937529","https://openalex.org/I223822909","https://openalex.org/I2802164966","https://openalex.org/I4210111460"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Guy Ungerechts","raw_affiliation_strings":["National Center for Tumor Diseases, Heidelberg, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"National Center for Tumor Diseases, Heidelberg, Germany","institution_ids":["https://openalex.org/I4210111460"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5056515547","display_name":"Christian J. Buchholz","orcid":"https://orcid.org/0000-0002-9837-7345","observed_orcids":["https://orcid.org/0000-0002-9837-7345"]},"institutions":[{"id":"https://openalex.org/I4391767962","display_name":"Deutsches Konsortium f\u00fcr Translationale Krebsforschung","ror":"https://ror.org/02pqn3g31","country_code":"DE","type":"facility","lineage":["https://openalex.org/I4391767962","https://openalex.org/I4405256427"]},{"id":"https://openalex.org/I884002606","display_name":"Paul Ehrlich Institut","ror":"https://ror.org/00yssnc44","country_code":"DE","type":"facility","lineage":["https://openalex.org/I884002606"]}],"countries":["DE"],"is_corresponding":true,"raw_author_name":"Christian J. Buchholz","raw_affiliation_strings":["German Cancer Consortium (DKTK), Heidelberg, Germany","Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"German Cancer Consortium (DKTK), Heidelberg, Germany","institution_ids":["https://openalex.org/I4391767962"]},{"raw_affiliation_string":"Molecular Biotechnology and Gene Therapy, Paul-Ehrlich-Institut, Langen, Germany","institution_ids":["https://openalex.org/I884002606"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5056515547"],"corresponding_institution_ids":["https://openalex.org/I4391767962","https://openalex.org/I884002606"],"apc_list":{"value":2490,"currency":"USD","value_usd":2490},"apc_paid":{"value":2490,"currency":"USD","value_usd":2490},"fwci":4.3158,"has_fulltext":true,"cited_by_count":57,"citation_normalized_percentile":{"value":0.95190722,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":97,"max":99},"biblio":{"volume":"9","issue":null,"first_page":"52","last_page":"52"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T10613","display_name":"Virus-based gene therapy research","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/1311","display_name":"Genetics"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10580","display_name":"Immunotherapy and Immune Responses","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.00039999998989515007,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/immune-checkpoint-inhibitors","display_name":"immune checkpoint inhibitors","score":0.9679999947547913},{"id":"https://openalex.org/keywords/tumor-specific-gene-delivery","display_name":"tumor-specific gene delivery","score":0.7350000143051147},{"id":"https://openalex.org/keywords/pd-1","display_name":"PD-1","score":0.5410000085830688},{"id":"https://openalex.org/keywords/nivolumab","display_name":"nivolumab","score":0.9010000228881836},{"id":"https://openalex.org/keywords/renca-cells","display_name":"Renca cells","score":0.6389999985694885},{"id":"https://openalex.org/keywords/tissue-distribution","display_name":"tissue distribution","score":0.6129999756813049},{"id":"https://openalex.org/keywords/liver-targeting","display_name":"liver targeting","score":0.5389999747276306},{"id":"https://openalex.org/keywords/intravenous-administration","display_name":"intravenous administration","score":0.527999997138977},{"id":"https://openalex.org/keywords/intratumoral-administration","display_name":"intratumoral administration","score":0.7390000224113464},{"id":"https://openalex.org/keywords/combination-with-chemotherapy","display_name":"combination with chemotherapy","score":0.6069999933242798}],"concepts":[{"id":"https://openalex.org/C111599444","wikidata":"https://www.wikidata.org/wiki/Q213901","display_name":"Genetic enhancement","level":3,"score":0.6497327089309692},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.6134932041168213},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.5888616442680359},{"id":"https://openalex.org/C135983454","wikidata":"https://www.wikidata.org/wiki/Q2790163","display_name":"Gene delivery","level":4,"score":0.5876949429512024},{"id":"https://openalex.org/C3875195","wikidata":"https://www.wikidata.org/wiki/Q5099363","display_name":"Chimeric antigen receptor","level":4,"score":0.5358193516731262},{"id":"https://openalex.org/C123894998","wikidata":"https://www.wikidata.org/wiki/Q425158","display_name":"Fusion protein","level":4,"score":0.5165035128593445},{"id":"https://openalex.org/C15152581","wikidata":"https://www.wikidata.org/wiki/Q7833966","display_name":"Transduction (biophysics)","level":2,"score":0.5127726197242737},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.47862452268600464},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.44230008125305176},{"id":"https://openalex.org/C2777701055","wikidata":"https://www.wikidata.org/wiki/Q1427096","display_name":"Immunotherapy","level":3,"score":0.432603120803833},{"id":"https://openalex.org/C32470452","wikidata":"https://www.wikidata.org/wiki/Q2298489","display_name":"Viral vector","level":4,"score":0.42221567034721375},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.3743009865283966},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.34662166237831116},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.19883239269256592},{"id":"https://openalex.org/C40767141","wikidata":"https://www.wikidata.org/wiki/Q285697","display_name":"Recombinant DNA","level":3,"score":0.07617625594139099},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":5,"locations":[{"id":"doi:10.3389/fonc.2019.00052","doi":"https://doi.org/10.3389/fonc.2019.00052","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2019.00052","pdf_url":"https://www.frontiersin.org/articles/10.3389/fonc.2019.00052/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},{"id":"pmh:oai:europepmc.org:5389361","doi":null,"is_oa":true,"landing_page_url":"http://europepmc.org/pmc/articles/PMC6382738","pdf_url":null,"source":{"id":"https://openalex.org/S4306400806","display_name":"Europe PMC (PubMed Central)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1303153112","host_organization_name":"European Bioinformatics Institute","host_organization_lineage":["https://openalex.org/I1303153112"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"","raw_type":"Text"},{"id":"pmh:oai:pubmedcentral.nih.gov:6382738","doi":null,"is_oa":true,"landing_page_url":"https://www.ncbi.nlm.nih.gov/pmc/articles/6382738","pdf_url":null,"source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Front Oncol","raw_type":"Text"},{"id":"pmid:30838171","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/30838171","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in oncology","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:c9b2651adab048cc8ecea4b5e41846c3","doi":null,"is_oa":true,"landing_page_url":"https://doaj.org/article/c9b2651adab048cc8ecea4b5e41846c3","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-sa","license_id":"https://openalex.org/licenses/cc-by-sa","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":"Frontiers in Oncology, Vol 9 (2019)","raw_type":"article"}],"best_oa_location":{"id":"doi:10.3389/fonc.2019.00052","doi":"https://doi.org/10.3389/fonc.2019.00052","is_oa":true,"landing_page_url":"https://doi.org/10.3389/fonc.2019.00052","pdf_url":"https://www.frontiersin.org/articles/10.3389/fonc.2019.00052/pdf","source":{"id":"https://openalex.org/S2596394214","display_name":"Frontiers in Oncology","issn_l":"2234-943X","issn":["2234-943X"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","norway-1","poland-100","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320527","host_organization_name":"Frontiers Media","host_organization_lineage":["https://openalex.org/P4310320527"],"host_organization_lineage_names":["Frontiers Media"],"type":"journal"},"license":"cc-by","license_id":"https://openalex.org/licenses/cc-by","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Frontiers in Oncology","raw_type":"journal-article"},"sustainable_development_goals":[{"score":0.9940000176429749,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G4021535106","display_name":"Chimeric Antigen Receptors (CARs) for Advanced Therapies","funder_award_id":"667980","funder_id":"https://openalex.org/F4320320300","funder_display_name":"European Commission"},{"id":"https://openalex.org/G434337789","display_name":null,"funder_award_id":"HORIZON2020","funder_id":"https://openalex.org/F4320320300","funder_display_name":"European Commission"},{"id":"https://openalex.org/G5705860826","display_name":null,"funder_award_id":"667980","funder_id":"https://openalex.org/F4320332999","funder_display_name":"Horizon 2020 Framework Programme"}],"funders":[{"id":"https://openalex.org/F4320310707","display_name":"Wilhelm Sander-Stiftung","ror":"https://ror.org/02q83sc19"},{"id":"https://openalex.org/F4320320300","display_name":"European Commission","ror":"https://ror.org/00k4n6c32"},{"id":"https://openalex.org/F4320332999","display_name":"Horizon 2020 Framework Programme","ror":"https://ror.org/00k4n6c32"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2912515633.pdf","grobid_xml":"https://content.openalex.org/works/W2912515633.grobid-xml"},"referenced_works_count":49,"referenced_works":["https://openalex.org/W837049827","https://openalex.org/W1153412892","https://openalex.org/W1568317937","https://openalex.org/W1678477267","https://openalex.org/W1901785997","https://openalex.org/W1950618346","https://openalex.org/W1973733861","https://openalex.org/W1981130347","https://openalex.org/W1984545852","https://openalex.org/W1994064996","https://openalex.org/W2001248362","https://openalex.org/W2008923083","https://openalex.org/W2016523043","https://openalex.org/W2016983859","https://openalex.org/W2023606978","https://openalex.org/W2033577259","https://openalex.org/W2110099898","https://openalex.org/W2118471749","https://openalex.org/W2126115955","https://openalex.org/W2129244956","https://openalex.org/W2129583958","https://openalex.org/W2131640081","https://openalex.org/W2141594276","https://openalex.org/W2146488455","https://openalex.org/W2154610258","https://openalex.org/W2155464214","https://openalex.org/W2173709025","https://openalex.org/W2177405394","https://openalex.org/W2209812019","https://openalex.org/W2233607944","https://openalex.org/W2277129094","https://openalex.org/W2528303838","https://openalex.org/W2560827811","https://openalex.org/W2580051840","https://openalex.org/W2596479132","https://openalex.org/W2597772749","https://openalex.org/W2735041159","https://openalex.org/W2737472918","https://openalex.org/W2744859856","https://openalex.org/W2759521620","https://openalex.org/W2783502825","https://openalex.org/W2792588868","https://openalex.org/W2876131254","https://openalex.org/W2916149495","https://openalex.org/W4240904506","https://openalex.org/W4255130209","https://openalex.org/W4321491322","https://openalex.org/W6676559011","https://openalex.org/W6704857805"],"related_works":["https://openalex.org/W4381850529","https://openalex.org/W4224442125","https://openalex.org/W7135219618","https://openalex.org/W3110771880","https://openalex.org/W2505792966","https://openalex.org/W4366281332","https://openalex.org/W4293414870","https://openalex.org/W1987616583","https://openalex.org/W6987967964","https://openalex.org/W2914352043"],"abstract_inverted_index":{"Immune":[0],"checkpoint":[1],"inhibitors":[2],"(ICIs)":[3],"can":[4,70,329],"block":[5],"distinct":[6],"receptors":[7],"on":[8,66],"T":[9,16],"cells":[10,13,273,279],"or":[11],"tumor":[12,20,96,168,204,227,318],"thus":[14,183],"preventing":[15],"cell":[17,100,123,142],"inactivation":[18],"and":[19,145,179,208,268,276,291,315],"immune":[21],"escape.":[22],"While":[23],"the":[24,86,95,111,141,195,239,245,250,309,321],"clinical":[25,240],"response":[26],"to":[27,53,94,149,238,317],"treatment":[28],"with":[29,41,73,219,333],"ICIs":[30,312],"in":[31,140,155,180,190,203,213,274,287],"cancer":[32],"patients":[33],"is":[34,38,49,255],"impressive,":[35],"this":[36],"therapy":[37],"often":[39],"associated":[40],"a":[42,51,67,89,115,221],"number":[43],"of":[44,57,60,63,114,131,199,226,249,299,311,323,336],"immune-related":[45],"adverse":[46],"events.":[47],"There":[48],"therefore":[50],"need":[52],"explore":[54],"innovative":[55],"strategies":[56],"tumor-specific":[58],"delivery":[59,166],"ICIs.":[61],"Delivery":[62],"therapeutic":[64,251],"proteins":[65],"genetic":[68],"level":[69],"be":[71,330],"accomplished":[72],"viral":[74],"vectors":[75,189],"including":[76],"those":[77],"derived":[78],"from":[79,270,277,313],"adenovirus-associated":[80],"virus":[81],"(AAV).":[82],"Here,":[83],"we":[84,109,304],"assessed":[85],"tumor-targeted":[87],"Her2-AAV,":[88],"receptor-targeted":[90],"AAV":[91,325],"vector":[92],"binding":[93,148],"antigen":[97],"Her2/neu":[98],"for":[99,104,206,215,223,231,307],"entry,":[101],"as":[102,173,282,284],"vehicle":[103],"ICI":[105,200],"gene":[106,165,177],"delivery.":[107],"Initially,":[108],"packaged":[110],"coding":[112,247],"sequence":[113,248],"scFv-Fc":[116],"fusion":[117],"protein":[118],"directed":[119,256],"against":[120,257],"mouse":[121],"programmed":[122],"death":[124],"protein-1":[125],"(PD-1)":[126],"into":[127,167],"Her2-AAV.":[128,216],"Upon":[129],"transduction":[130],"Her2/neu+":[132],"RENCA":[133,160],"cells,":[134],"AAV-encoded":[135],"\u03b1PD-1":[136,196],"was":[137,229],"readily":[138],"detectable":[139],"culture":[143],"supernatant":[144],"revealed":[146],"specific":[147,164],"its":[150],"target":[151],"antigen.":[152],"In":[153,302],"vivo,":[154],"BALB/c":[156],"mice":[157],"bearing":[158],"subcutaneous":[159],"tumors,":[161],"Her2-AAV":[162,188,207,232],"mediated":[163],"tissue":[169,205,319],"upon":[170,280],"intravenous":[171,285],"administration":[172,286],"verified":[174],"by":[175,187,320],"luciferase":[176],"transfer":[178],"vivo":[181],"imaging":[182],"demonstrating":[184],"unimpaired":[185],"tumor-targeting":[186],"immunocompetent":[191],"animals.":[192],"When":[193,217],"delivering":[194],"gene,":[197],"levels":[198,293],"were":[201,260,266,294],"similar":[202],"AAV2":[209],"but":[210],"substantially":[211],"reduced":[212,224],"liver":[214,314],"combined":[218,332],"chemotherapy":[220],"tendency":[222],"progression":[225],"growth":[228],"documented":[230],"treated":[233],"mice.":[234],"To":[235],"get":[236],"closer":[237],"situation,":[241],"AAV-constructs":[242],"that":[243],"deliver":[244],"complete":[246],"antibody":[252],"Nivolumab":[253],"which":[254],"human":[258],"PD-1":[259],"generated":[261],"next.":[262],"The":[263],"AAV-Nivolumab":[264],"constructs":[265],"expressed":[267],"released":[269],"transduced":[271],"MDA-MB-453":[272],"vitro":[275],"RENCA-Her2/neu":[278],"intratumoral":[281],"well":[283],"vivo.":[288],"Antibody":[289],"processing":[290],"expression":[292],"further":[295],"improved":[296],"through":[297],"optimization":[298],"construct":[300],"design.":[301],"conclusion,":[303],"provide":[305],"proof-of-principle":[306],"redirecting":[308],"biodistribution":[310],"serum":[316],"use":[322],"engineered":[324],"vectors.":[326],"This":[327],"strategy":[328],"easily":[331],"other":[334],"types":[335],"immunotherapeutic":[337],"concepts.":[338]},"counts_by_year":[{"year":2026,"cited_by_count":4},{"year":2025,"cited_by_count":5},{"year":2024,"cited_by_count":9},{"year":2023,"cited_by_count":9},{"year":2022,"cited_by_count":9},{"year":2021,"cited_by_count":10},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":4}],"updated_date":"2026-11-04T10:54:05.112534","created_date":"2019-02-21T00:00:00"}